We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBE SCIENTIFIC, LLC

Download Mobile App




Pneumocystis Frequently Found Lethal in Dermatomyositis

By LabMedica International staff writers
Posted on 25 Sep 2021
The term idiopathic inflammatory myopathy (IIM) denotes a group of autoimmune diseases characterized by myasthenia and typical skin rash, among which dermatomyositis (DM) and polymyositis (PM) are the most common.

Idiopathic inflammatory myopathies (IIM) are associated with a significantly higher risk of opportunistic infections including Pneumocystis jirovecii pneumonia (PJP), a potentially fatal opportunistic infection. More...
In patients with rheumatic immune diseases, most PJP occurs in the first three months after initiating immunosuppressive therapy.

A team of Rheumatologists at the Renji Hospital (Shanghai, China) prospectively followed 463 consecutive patients with IIM a period of at least one year to analyze the incidence of PJP. In the second part of the study, they enrolled 30 consecutive PJP patients with any rheumatic disease in order to identify the mortality rate and risk factors. The diagnosis of PJP was based on comprehensive evaluation by clinical manifestations such as fever or acute dyspnea, characteristic radiographic findings, and etiological evidence. For confirmation, a case needed to have positive microbiological tests such as by next-generation sequencing and Grocott-Gomori methenamine-silver staining of bronchoalveolar lavage fluid.

The team reported that the prevalence of PJP in IIM patients was found to be 3.0/100 person-years, while in anti-melanoma differentiation-associated gene 5 antibody positive (MDA5+) DM patients it was 7.5/100 person-years and in MDA5− IIM patients 0.7/100 person-years. PJP typically occurred in the first two months in the case of MDA5+ DM patients who had a significant decrease in their CD4+ T cell counts and lymphocyte counts. In PJP patients, 3-month mortality was higher for MDA5+ DM patients than in those with other rheumatic diseases (83.3% versus 38.9%). Worryingly, MDA5+ DM patients seemed not to benefit from prompt anti-PJP treatment, unlike patients with other rheumatic diseases whose survival improved when anti-PJP treatment was started within six days.

The authors concluded that the MDA5+ DM patients are highly susceptible to infection with Pneumocystis jirovecii, which is also harder to cure than in other rheumatic diseases. The reason for the higher incidence and mortality may be related to the lower CD4+ T cell counts and progressive interstitial lung disease in MDA5+ patients. The study was published on September 4, 2021 in the journal Arthritis Research & Therapy.

Related Links:

Renji Hospital


New
Gold Member
Serological Pipets
INTEGRA Serological Pipets
Serological Pipet Controller
PIPETBOY GENIUS
New
Autoimmune Disease Diagnostic
Chorus ds-DNA-G
New
Silver Member
Quality Control Material
Multichem ID-B
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.